Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer tend to be more aggressive among all breast cancers. Breast cancers with HER2 gene amplification or HER2 protein overexpression are called HER2-positive. It tends to grow faster and are more likely to spread and come back compared to HER2-negative breast cancers. HER2 positive breast cancer is often treated with chemotherapy drugs called anthracylines (e.g. doxorubicine, epirubicine), taxanes (e.g. Docetaxel, peclitaxel) as well as some others, usually in combination of two or more chemotherapy drugs 1 but the development of potential drug delivery system by using nanotechnology is also the important aspect for the proper treatment of HER2 positive breast cancer. The aim of this study was to develop DTX-loaded self assembled nanocarriers (SANs) for treatment of HER2 positive breast cancer and also to evaluate their efficacy to release the drug by controlled manner. SANs were prepared from a glyceryl monooleate, Pluronic® F127 (0.5 -1.5 % w/v) and Pluronic® F68 (0.25-1.0 %w/v) in different concentration with or without docetaxel trihydrate (DTX) (2.0%w/v) by high pressure homogenization, before preparation compatibility of drug and polymers was studied by differential scanning calorimetry (DSC) and FTIR spectroscopy. Prepared SANs was then subject to different evaluation test particle size, zeta potential, % entrapment efficiency, drug content, in vitro drug release study, measurement of pH, and stability study. Particle size of SANs prepared with Pluronic® F127 was found in the range of 170 nm to 280 nm whereas SANs with Pluronic® F68 was found between 200 to 240 nm and it shows more negative zeta potential value than -30 mV. More than 90 % of DTX was found to be entrapped in SANs formulations loaded with DTX 2.0% w/v. Drug released study revealed that formulation F9 containing 0.25% PF68 shows 89.59 % release after 12 h and F5 containing 1.0% PF127 releases 96.56% drug after 12 h. Results of one month stability study shows that the SANs formulations were found to be stable over a one month. Hence, the DTX-loaded SANs was act as an potential drug carrier to fulfill the demand of cancer therapeutics.
INTRODUCTION
Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer tend to be more aggressive among all breast cancers. Breast cancers with HER2 gene amplification or HER2 protein over expression are called HER2-positive. The HER2 gene makes HER2 proteins. HER2 proteins are receptors on breast cells. Normally, HER2 receptors help control how a healthy breast cell grows, divides, and repairs itself. But in about 25% of breast cancers, the HER2 gene doesn't work correctly and makes too many copies of it ISSN: 2250-1177
[2] CODEN (USA): JDDTAO (known as HER2 gene amplification). All these extra HER2 genes tell breast cells to make too many HER2 receptors (HER2 protein over expression). This makes breast cells grow and divide in an uncontrolled way. HER2-positive breast cancers tend to grow faster and are more likely to spread and come back compared to HER2-negative breast cancers.
Between 15 and 25 out of every 100 women with breast cancer (15-25%) have HER2 positive cancers. Fewer men with breast cancer are thought to have HER2 positive cancers. There are some treatments available specifically for HER2-positive breast cancer. There are different groups of chemotherapy drugs. HER2 positive breast cancer is often treated with chemotherapy drugs called anthracylines (e.g. doxorubicine, epirubicine), taxanes (e.g. Docetaxel, peclitaxel) as well as some others, usually in combination of two or more chemotherapy drugs 1 but the development of potential drug delivery system by using nanotechnology is also the important aspect for the proper treatment of HER2 positive breast cancer. There are number of nanoparticulate drug delivery system available for the delivery of anticancer agents but the Self-assembled nanocarriers (SANs) have more potential than the other drug delivery system. SANs are bicontinuous cubic phase liquid crystals have many properties that make them appealing as a universal vehicle for drug delivery. These are nanoparticles, more accurately nanostructure particles, or self-assembled liquid crystalline particles with a solid-like rheology 2 . In recent years, SANs were considered as the drug nanocarrier due to their great potential as an alternative drug delivery system relative to liposome. The stability is another drawback in fabrication of liposome however colloidal dispersions of SANs can be stabilized by the addition of polymers. They also possess the potential for controlled delivery of actives, where diffusion is governed by the tortuous diffusion of the active through the "regular" channel structure of the cubic phase. SANs possess a sufficient average degree of molecular orientation in order to characterize by structural symmetry, and often form in aqueous surfactant system at relatively high ampiphile concentrations.
SANs especially made of binary systems, monooleinwater 3 . That can self-assemble into thermodynamically stable biocontinuous cubic liquid crystallize phases 4 . These are capable of loading lipophilic, hydrophilic, and amphiphilic drugs. Their three dimension nanostructure with hydrophobic and hydrophilic domains increases their importance in novel drug pharmaceutical drug delivery.
These systems include liquid crystalline aggregates or cross-linked gel networks that load, stabilize and ultimately deliver active ingredients. Incorporation of drugs into the complex internal domains of these structures can facilitate diffusion controlled release of drug into the surrounding external aqueous environment [5] [6] [7] . The large interfacial area can provide a complex diffusion pathway for sustained release of entrapped drug molecules, whereas lipid constituents are biocompatible, bioadhesive, and digestible 8, 9 .
The aim of this study was to develop DTX-loaded SANs for treatment of HER2 positive breast cancer and also to evaluate their efficacy to release the drug by controlled manner.
MATERIALS AND METHOD
Docetaxel trihydrate (DTX) was obtained as a gift sample from Scino Pharmaceutical Pvt., Taiwan. Glyceryl monooleate was obtained from Otto Chemie., Mumbai (India). Pluronic® F127 (PF127) obtained from Research Lab Fine Chem Industries, Mumbai(India), and Pluronic® F68 (PF68) was obtained from Himedia Laboratory Pvt. Ltd. Water was purifiedon a Milli-Q system obtained from a Millipore® synergy system (Millipore, Billerica, Massachusetts, USA). All other chemicals used were of analytical grade.
Preparation of SANs
SANs were prepared by method described in our previous publication 10 from a glyceryl monooleate and Pluronic® F127 melt with or without drug. Glyceryl monooleate and Pluronic® F127 were melted at 60°C until homogenous at a ratio of glyceryl monooleate to Pluronic® F127 of 9:1 (w/w). DTX was loaded by preparing drug solution in required volume of ethanol for dissolution. To this mixture 5.0ml of ethanol was added as a hydrotropic solvent.
To prepare the self-assembled nanocarriers dispersion, the low viscosity homogenous melt was either added drop wise or injected into excess water such that the concentration of lipid in the sample was approximately 8-10% (w/w) with continuous stirring on magnetic stirrer and volume was made up to 100.0 ml with distilled water. Samples were allowed to equilibrate at room temperature for overnight. The samples were then homogenized for 2 min using homogenizer at 1500-2000 rpm because much more homogenization may hamper the cubic crystal structure. Sterilization was done in autoclave at 121°C, 15lb pressure for 20 min. Prepared self-assembled nanocarriers dispersion stored in glass vial at room temperature. Same procedure was repeated for preparation of self-assembled nanocarriers with Pluronic® F68 as shown in Table. 1. Though Pluronic® have a gelling property, it does not show any type of gelation during self-assembled nanocarriers formation as it was used in very small concentration.
Drug-Excipients Compatibility Studies

Thermal Analysis
The drug, the polymers, and their physical mixtures with DTX were analyzed by differential scanning calorimetry (DSC). Open pan DSC measurements were carried out using a DSC Q20 (TA Instruments Inc., New Castle, DE) with a sample size of approximately 5 mg weighed into each aluminum pans. Samples were heated at 10°C/ min from 0 to 400°C. Nitrogen at a flow rate of 40 mL/ min was used as a purge gas in DSC analyses. The results were analyzed using the Universal Analysis software version 4.5A; build 4.5.0.5 (TA Instruments, Inc., New Castle, DE, USA).
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FTIR Spectroscopy
To determine any possible interactions, the physical mixtures of the drug and the polymers were analyzed using the Fourier transformed infrared (FTIR) spectroscopy.
Briefly, the samples were dried in a hot air oven at 50°C for 2 h. The samples were mixed with KBr and subject to scanning in the range of 400 to 4000 cm−1. Infrared spectra of drug, polymer and their physical mixture were obtained from an FTIR spectrophotometer (Model: IR Prestige-21, Shimadzu, Japan) equipped with an attenuated total reflectance (ATR) accessory. The influence of the residual moisture was theoretically removed by subjecting the samples to vacuum drying before obtaining any spectra. Each sample analysis included 45 scans, at a resolution of 4 cm −1 from 4500 to 400 cm −1 . The shifts in the spectra of the drug in the presence of polymers and other components were investigated to determine physical interactions between the drug and the polymers, if any.
Evaluation of SANs
Particle size determination 10 Particle size analysis of dispersions was performed using a Zeta sizer 3000 PCS (Malvern Instr., England) equipped with a 5 mW helium neon laser with a wavelength output of 633 nm. Measurements were made at 25°C, angle 90°, run time at least 40-80 sec and water used as a dispersant. Data interpreted by method of cumulants.
Zeta potential measurement 10,
Zeta potential measurement of SANs dispersion was performed by using Zeta Potentiometer (Malvern Instr., England) equipped with a 5 mW helium neon laser with a wavelength output of 633 nm. Measurements were made at 25°C, angle 90°, 10-15 runs and water used as a dispersant.
Entrapment efficiency 11 The sample of SANs dispersion was transferred to the centrifuge tubes and put to 1500 rpm for 2 h. Nonentrapped drug or free drug in solution leaked outside the sub-tubes, making it possible to measure its concentration in solution, and thus allowed the deduction of the drug encapsulated in SANs. That UV absorbance was used to compute Ct (namely, total concentration) and the UV absorbance of DTX contained in filtrate after centrifuge was used to compute Cf (namely, filtrate concentration). Thus, the % entrapment efficiency was calculated as follows:
Drug content of SANs
11, 12
Each formulation (1.0 ml) equivalent to 20 mg was taken in a 100ml volumetric flask diluted with PBS (pH 7.4) and shaken to until it gets dissolve otherwise sonicated for 30 min. The solution was filtered through whattman filter paper, 1 ml of above filtrate was pipette out and diluted to 10 ml with phosphate PBS (pH 7.4). The content of the drug was estimated spectrophotometrically by using standard curve plotted at 220 nm.
In vitro drug release study 11 Drug release from SANs dispersion was carried out by using Franz diffusion cell. It consists of two compartment i.e., Donor compartment (cell cap) and receptor compartment. Previously activated semi permeable membrane (cellophane membrane) is placed between these two compartments. Dispersion was added into the donor compartment above cellophane membrane. Receptor compartment consist of stirring bar and sampling port having 18 ml capacity.
The receptor compartment containing 18 ml PBS solution (pH 7.4) and maintained temperature at 37 + 0.5 0 C at predetermined time points, 1ml of sample was withdrawn from the receptor compartment, replacing the sampled volume with same volume of PBS pH 7.4 after each sampling for a period of 10-12 h. The samples were suitably diluted and measured spectrophotometrically at 220 nm. The concentration of drug was determined from a previously constructed calibration curve.
Determination of pH
The pH of SANs dispersions was determined at room temperature using digital pH meter, model NIG-333. pH meter was calibrated using 9.2 pH and 4.0 pH buffer solutions. All the studies were repeated in triplicate with good agreement being found between measurements.
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Stability study
The stability study of selected formulation was done at 40 0 C with 75% RH and room temperature and also in freezing temperature. The test parameters such as integrity, phase separation, pH measurement was carried out as a stability parameter after a specific time interval and drug precipitation were determined at every week till one month. Particle size determination was conducted at different time interval in order to evidence possible variations in mean diameter of SANs over time of one month.
RESULT AND DISCUSSION
Drug-Excipients Compatibility Studies Thermal Analysis
The DSC thermogram of pure DTX showed a sharp endothermic peak at ∼169°C, corresponding to DTX melting point (thermograms not shown). Additionally, the DSC thermograms of Pluronic® F127 and Pluronic® F68 revealed sharp endothermic peaks at temperatures of ∼58 and ∼56°C, respectively.
The DSC analysis of the physical mixtures, DTX: Pluronic® F127 (1:1), and DTX: Pluronic® F68 (1:1), revealed a negligible and a non-significant change in the thermal behavior of DTX in the presence of these polymers. Additionally, the melting signals (endotherm) of Pluronic® F127, and Pluronic® F68 were clearly distinguishable in the physical mixtures of the respective polymers with DTX. The absence of any other endothermic peak over the entire temperature range thus excluded any physical interaction or obvious incompatibility between the drug and the polymers. The DSC results thus indicated the suitability of these polymers to be used in the prepared formulations. 
Evaluation of SANs
Particle size
Particle size of SANs F1 F2 F3 F4 F5 prepared by Pluronic® F127 in the concentration 0.5%, 1.0%, 1.5% without drug and 0.5%, 1.0% with drug DTX was found to be in the range of 170 nm to 280 nm. While Particle size of SANs F6, F7, F8, F9, F10 prepared by Pluronic® F68 in the concentration 0.25%, 0.5%,1.0%, 1.5% without drug and 0.25% with drug DTX were found to be in the range of 200 nm to 240 nm.
Zeta Potential
Particles with zeta potentials more negative than -30mV are normally considered stable. The results of zeta potential measurement of SANs dispersion revealed that formulation F1 and F7 shows more negative zeta potential value about -54.1 mV and -47.4 mV respectively.
Determination of pH
Formulations F1, F2 , F3 , F4, F5 and F6, F7, F8, F9, F10 shows pH in the normal range of 6.5 to 7.5 whereas pH of formulation prepared by Pluronic® F68 (F6-F10 ) was found to be more than that of Pluronic® F127 (F1-F5).
Entrapment efficiency
The drug entrapment efficiency is an important parameter for drug delivery systems. The % entrapment efficiency of the DTX loaded SANs was found to be 95.67 ± 2.0, 94.74 ± 2.0 and 91.95 ± 1.8 (%w/w) for 
Drug content
The results obtained in drug content determination for different formulations revealed that the drug content F4, F5 and F10 was found to be more than 95% to the amount of drug loading. It means that, the entire drug was well uniformly distributed. The percentage relative standard deviation (% RSD) is less than 2% indicates the reproducibility of process used for further formulation.
In vitro drug release study
On the basis of results obtained during above evaluation parameters the formulations containing 1.0% Pluronic® F127 and 0.25% Pluronic® F68 were selected for the further study of drug release. The results of drug released study revealed that formulation F9 containing 0.25% PF68 shows 89.59 % release after 12 h and F5 containing 1.0% PF127 releases 96.56% drug after 12 h, it means that formulation F9 prepared with 0.25 % Pluronic® F68 shows more sustained release as compared to F5 containing 1.0% PF 127 and might have efficiency to releases drug more than 12h however, plane DTX-solution shows complete release within 4h as shown in Figure 3 .
Stability Study
The SANs dispersion prepared by both Pluronic® F127 and Pluronic® F68 appears milky white and odorless. After production and elimination of large particles by filtration, dispersion was stored in glass vials at room temperature in dark, 40°C with 75% RH and also at freezing temperature. In order to assess the physical stability of SANs dispersion, organoleptic and morphological aspects such as phase separation and formation of precipitates were investigated as a function of time. The organoleptic and morphological aspects of SANs dispersion were found to be unchanged with time; and SANs dispersion was found to be free from phase separation phenomena for more than one month. Results of one month stability study shows that pH of formulations prepared using Pluronic® F127 and Pluronic® F68 showed slightly decreases in pH after one month as compared to pH values at initial time. But not significant change was observed after one month storage at at different storage condition. According to results obtained for formulations F1, F2, F3 the very slight change in particle size was observed and did not exceed 290.3 nm while formulations F6, F7, F8 also shows very less changes in particle size and not exceed 233.4 nm.
CONCLUSION
The Docetaxel trihydrate loaded SANs prepared by PF127 was found to be more stable and effective than that of SANs prepared by PF68. The fabrication of nanoparticulate drug delivery containing SANs is the need of breast cancer therapy. To overcome the drawbacks concern with the bioavailability of docetaxel trihydrate, the formulation of SANs delivery system was found to be best approach in the designing of novel controlled release drug delivery system. The DTX-loaded SANs was act as an potential drug carrier to fulfill the demand of cancer therapeutics.
